LPTX - Leap Therapeutics, Inc. Price to Earnings Adjusted for Growth Rate

Corporate company logo of Leap Therapeutics, Inc. (LPTX)

Leap Therapeutics, Inc. (LPTX) is facing a liquidity shortage due to research expenditures, which is depleting its reserves. The company is implementing waste filtration and optimizing transportation to comply with environmental regulations. The PEG ratio demonstrates valuation volatility, where 0.00 serves as the final level mark. This chart highlights the risks associated with the uncertainty of DKN-01 drug trials and the dependence on external financing.

LPTX: Leap Tx PEG Multiple 07/04/2022 - 11/13/2025

Metric breakdowns and analytics for Leap Therapeutics Inc (LPTX)

- market value and analyst target forecast:
Summary company analytics:LPTX Leap Therapeutics, Inc.
Original product of Leap Therapeutics

The PEG ratio compares a company's market value with its earnings growth, identifying undervalued assets. For Leap Therapeutics, Inc. (LPTX), this calculation is critical when scaling its antibody portfolio and conducting phase II clinical trials. Analyzing the P/E ratio relative to earnings growth rates allows for an objective valuation of the business against the speed of therapy development. Values below one signal potential for share price growth, providing a foundation for investment capital stability.

Competitors of Leap Therapeutics, Inc.

ImmunityBio, Inc. (IBRX) - Price to Net Income Growth Ratio|Immunocore Holdings - Price/Earnings to Growth Multiple|Janux Therapeutics, Inc. (JANX) - Price to Earnings Adjusted for Growth Rate|RCUS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ZYME (Zymeworks)|TNGX: PEG Multiple|IOVA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio immatics.com|Price/Earnings to Growth Multiple xencor.com (XNCR)|Price/Earnings to Growth Ratio Compass Therapeutics Inc (CMPX)|Price/Earnings to Growth Multiple Replimune Corp REPL|Lyell - Price/Earnings to Growth Multiple|PEG Multiple Innate Pharma S.A IPHA|PYXS - Price/Earnings to Growth Ratio|CGEN (Compugen) - Growth-Adjusted P/E Ratio|IO Biotech Inc. (IOBT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Sutro Bio (STRO)|Price/Earnings to Growth Multiple INKT|HOWL - Price to Net Income Growth Ratio|Price/Earnings to Growth Multiple IMMX (Immix Biopharma, Inc.)|Company Value to Earnings Growth Ratio ALXO|PEG Multiple CUE (Cue Biopharma Inc.)|Growth-Adjusted Payback Ratio PDSB|Sonnet BioTherapeutics Holdings Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate MAIA Bio|Liminatus Pharma (LIMN) - Price/Earnings to Growth Ratio|LAVA Therapeutics NV - Growth-Adjusted Payback Ratio|NXTC (nextcure.com) - PEG Multiple|PEG Multiple intensitytherapeutics.com|Price/Earnings to Growth Ratio senseibio.com (SNSE)|TOVX: Market Cap to Earnings and Growth Ratio|Gritstone bio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kinetabio.com (KA)|NEXI - Price/Earnings to Growth Ratio|Turnstone Biologics Corp - Company Value to Earnings Growth Ratio|VCNX: PEG Multiple|Harpoon Therapeutics Corp (HARP) - PEG Multiple